Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 18785202 
Zhu H, et al. (2008) 15-lipoxygenase-1 activates tumor suppressor p53 independent of enzymatic activity. Int J Cancer 123, 2741-9 18785202
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Download Sites

S15-p - p53 (human)
Orthologous residues
p53 (human): S15‑p, p53 (mouse): S15‑p, p53 iso2 (mouse): S18‑p, p53 (rat): S15‑p, p53 (rabbit): S15‑p, p53 (monkey): S15‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  colorectal cancer, colorectal carcinoma
 Relevant cell lines - cell types - tissues:  HCT116 (intestinal)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ALOX15 (human) increase wild-type ALOX15
ALOX15 (human) no effect upon treatment-induced increase inactive ALOX15
wortmannin inhibit treatment-induced increase
DNAPK (human), ALOX15 (human) augment treatment-induced increase AZLOX15 binds to DNA-PK and increases activity and S15 p53 phosphorylation.
siRNA DNAPK (human) inhibit treatment-induced increase


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.